Prohibited substance raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
UK-414,495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414,495 acts as a potent, selective inhibitor of the enzyme neutral endopeptidase, which normally serves to break down the neuropeptide VIP. The consequent increase in VIP activity alters blood flow to the genital region leading to increased lubrication and muscle relaxation.
Coenzyme Q (CoQ ), also known as ubiquinone, is a naturally occurring biochemical cofactor (coenzyme) and an antioxidant produced by the human body. The human body mainly produces the form known as coenzyme Q10 (CoQ10, ubidecarenone), but other forms exist. CoQ is used by and found in many organisms, including animals and bacteria. As a result, it can also be obtained from dietary sources, such as meat, fish, seed oils, vegetables, and dietary supplements. CoQ plays a role in mitochondrial oxidative phosphorylation, aiding in the production of adenosine triphosphate (ATP), which is involved in energy transfer within cells. The structure of CoQ10 consists of a benzoquinone moiety and an isoprenoid side chain, with the "10" referring to the number of isoprenyl chemical subunits in its tail. Although a ubiquitous molecule in human tissues, CoQ10 is not a dietary nutrient and does not have a recommended intake level, and its use as a supplement is not approved in the United States for any health or anti-disease effect.
The internal C (cysteine) residue attacks the peptide carboxyl on the final residue of the N-extein (nucleophilic displacement). Transesterification occurs when the first residue of the C-extein attacks the newly formed thioester. The rest proceeds as usual. The mechanism for the splicing effect is a naturally occurring analogy to the technique for chemically generating medium-sized proteins called native chemical ligation.
United States politicians' agenda against LSD usage had swept psilocybin along with it into the Schedule I category of illicit drugs. Such restrictions on the use of these drugs in human research made funding for such projects difficult to obtain, and scientists who worked with psychedelic drugs faced being "professionally marginalized". Although Hofmann tested these compounds on himself, he never advocated their legalization or medical use. In his 1979 book LSD – Mein Sorgenkind (LSD, My Problem Child), he described the problematic use of these hallucinogens as inebriants. Despite the legal restrictions on psilocybin use, the 1970s witnessed the emergence of psilocybin as the "entheogen of choice". This was due in large part to wide dissemination of information on the topic, which included works such as those by Carlos Castaneda and several books that taught the technique of growing psilocybin mushrooms. One of the most popular of the latter group, Psilocybin: Magic Mushroom Grower's Guide, was published in 1976 under the pseudonyms O. T. Oss and O. N. Oeric by Jeremy Bigwood, Dennis J. McKenna, K. Harrison McKenna, and Terence McKenna. Over 100,000 copies were sold by 1981. As ethnobiologist Jonathan Ott explains, "These authors adapted San Antonio's technique (for producing edible mushrooms by casing mycelial cultures on a rye grain substrate; San Antonio 1971) to the production of Psilocybe [Stropharia] cubensis.
Sources: en.wikipedia.org
{\displaystyle \int \limits _{\partial \Omega }\left(\mu {\frac {\partial \mathbf {u} }{\partial {\hat {\mathbf {n} }}}}-p{\hat {\mathbf {n} }}\right)\cdot \mathbf {v} =\underbrace {\int \limits _{\Gamma _{D}}\left(\mu {\frac {\partial \mathbf {u} }{\partial {\hat {\mathbf {n} }}}}-p{\hat {\mathbf {n} }}\right)\cdot \mathbf {v} } _{\mathbf {v} =\mathbf {0} {\text{ on }}\Gamma _{D}\ }+\int \limits _{\Gamma _{N}}\underbrace {{\vphantom {\int \limits _{\Gamma _{N}}}}\left(\mu {\frac {\partial \mathbf {u} }{\partial {\hat {\mathbf {n} }}}}-p{\hat {\mathbf {n} }}\right)} _{=\mathbf {h} {\text{ on }}\Gamma _{N}}\cdot \mathbf {v} =\int \limits _{\Gamma _{N}}\mathbf {h} \cdot \mathbf {v} .}
In the wake of the rebel capture of Damascus, several places in the capital were ransacked, including Iran's embassy, Assad's estates, and government offices; the Central Bank of Syria was besieged and the reception hall of the Presidential Palace was set on fire. Statues of Hafez al-Assad were toppled nationwide. The Russian and Chinese embassies were untouched. The rebels announced a 13-hour curfew in the capital amidst heavy armed rebel presence and traffic in the capital. Syrian State Television, now under rebel control, resumed broadcasting. Al-Assad clan members expressed resentment over the escape of Bashar and his close family, with one relative stating that "Everyone feels he betrayed them". Israel bombed the Mezzeh Air Base in Damascus. Another strike targeted an alleged Iranian research center used for missile development in the Kafr Sousa district. The Israeli army also crossed the border into Syria, seizing territory adjacent to the border after it was abandoned by the Syrian Army. HTS leader Ahmed al-Sharaa became the de facto leader of Syria on 8 December 2024 as the General Commander and head of the New Syrian Administration, serving until 29 January 2025, when he was appointed President of Syria by the Syrian General Command. Mohammed al-Bashir, head of the Syrian Salvation Government, was appointed prime minister of the Syrian caretaker government on 10 December and served until 29 March 2025.
== Modern herbal medicine == The World Health Organization (WHO) estimates that 80 percent of the population of some Asian and African countries presently uses herbal medicine for some aspect of primary health care. Some prescription drugs have a basis as herbal remedies, including artemisinin, digoxin, quinine and taxanes.
In land plants, chloroplasts are generally lens-shaped, 3–10 μm in diameter and 1–3 μm thick. Corn seedling chloroplasts are ≈20 μm3 in volume. Greater diversity in chloroplast shapes exists among the algae, which often contain a single chloroplast that can be shaped like a net (e.g., Oedogonium), a cup (e.g., Chlamydomonas), a ribbon-like spiral around the edges of the cell (e.g., Spirogyra), or slightly twisted bands at the cell edges (e.g., Sirogonium). Some algae have two chloroplasts in each cell; they are star-shaped in Zygnema, or may follow the shape of half the cell in order Desmidiales. In some algae, the chloroplast takes up most of the cell, with pockets for the nucleus and other organelles, for example, some species of Chlorella have a cup-shaped chloroplast that occupies much of the cell. All chloroplasts have at least three membrane systems—the outer chloroplast membrane, the inner chloroplast membrane, and the thylakoid system. The two innermost lipid-bilayer membranes that surround all chloroplasts correspond to the outer and inner membranes of the ancestral cyanobacterium's gram negative cell wall, and not the phagosomal membrane from the host, which was probably lost. Chloroplasts that are the product of secondary endosymbiosis may have additional membranes surrounding these three. Inside the outer and inner chloroplast membranes is the chloroplast stroma, a semi-gel-like fluid that makes up much of a chloroplast's volume, and in which the thylakoid system floats.
== Bibliography == Danish-language bibliography Rasmussen, Carsten Porskrog (2019). Hertugdømmet (in Danish). Aarhus Universitetsforlag. ISBN 978-87-7184-761-1. Gram-Andersen, Jesper (2020). De kongelige hertugdømmer: skydebrødre i Det Kongelige Kjøbenhavnske Skydeselskab og Danske Broderskab med relation til Slesvig og Holsten (in Danish). Kle-art. ISBN 978-87-92750-32-7. Jensen, N. P. (23 January 2019). Den første slesvigske krig 1848-50 (in Danish). Lindhardt og Ringhof. ISBN 978-87-26-10014-3. Buk-Swienty, Tom (2009). Slagtebænk Dybbøl: 18. april 1864 : historien om et slag (in Danish). Gyldendal A/S. ISBN 978-87-02-07756-8.< Frandsen, Steen Bo (2008). Holsten i helstaten: hertugdømmet inden for og uden for det danske monarki i første halvdel af 1800-tallet (in Danish). Museum Tusculanums Forlag, Københavns Universitet. ISBN 978-87-635-0754-7. Korsgaard, Ove (2024). Nationalstatens fødselsveer: Grundtvig, krig og geopolitik. Aarhus: Aarhus University Press. ISBN 978-87-7597-394-1. German language bibliography Wenners, Peter (2019). Schleswig-Holstein und Dänemark: Geschichte im Spiegel der Literatur (in German). Boyens. ISBN 978-3-8042-1513-9. Jung, Frank (1 September 2014). 1864 - Der Krieg um Schleswig-Holstein (in German). Ellert & Richter Verlag. ISBN 978-3-8319-1016-8. English language bibliography Svendsen, Nick B. (11 September 2018). Medieval wars in the Duchy of Schleswig 1410 to 1432: and the quest for the Nordic Countries. Books on Demand. ISBN 978-87-430-0687-9. Dicey, Edward; Lowe, Charles (9 June 2016).
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.